Specialty Pharmacy

Combination therapy to be assessed in multiple myeloma and solid cancers.

Systemic chemotherapy combined with immunotherapy negatively impacts the immune system compared with local chemotherapy plus immunotherapy.

New findings may improve drug development for autoimmune and inflammatory diseases.

Novo Nordisk and Glooko will create a digital health solution for diabetes management.

Top news of the day from across the health care landscape.

Low baseline vitamin D deficiency may decrease the effectiveness of rosuvastatin in adults with HIV.

In 2015, there were 17.5 million cases of cancer worldwide and 8.7 million cancer-related deaths.

Scientists solve structural details of HIV machinery.

Atezolizumab being examined as first-line treatment for individuals ineligible for cisplatin chemotherapy.

Combination approach better targets breast cancer tumors with PIK3CA gene mutations.

Brain shrinkage in patients with multiple sclerosis may be linked to leaked hemoglobin protein.

Children exposed to rheumatoid arthritis in utero saw elevated early and late childhood epilepsy risk.

Amgen's request for a permanent injunction granted to prohibit Sanofi/Regeneron from manufacturing and selling PCSK9 inhibitor.

Top news of the week in oncology and cancer drug development.

CanChew Plus CBD Gum to be tested in irritable bowel syndrome clinical trial.

Nonsteroidal anti-inflammatory drugs effective in preventing advanced neoplasia recurrence.

Antenatal ART significantly lowered early mother-to-child HIV transmission rates.

Combination therapy may help combat treatment resistance in cancer patients.

Genentech’s Lucentis granted fifth FDA approval.

Top articles of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

The FDA approved the lowest amount of new drugs since 2010 last year, with only 22 new drugs receiving approval.

HIV drug trial will evaluate cabotegravir’s performance as a pre-exposure prophylaxis.

ASN003 demonstrated potent action against tumor growth.

The Aptima HIV-1 Quant assay will significantly cut lab times.

Group-based acceptance and commitment therapy increased likelihood of effective coping strategies in diabetes patients.

Device helps surgeons distinguish between cancerous and non-cancerous tissues.

Combination treatment methods to cure HIV may have harmful side effects.